Targeting the Fibroblast Growth Factor Pathway in Molecular Subtypes of Castration-Resistant Prostate Cancer

In vitro/ex vivo analysis of erdafitinib and CH5183284 demonstrated robust and moderate growth suppression of androgen receptor-positive CRPC, respectively.